461 Studies Now Enrolling
A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)
Study to Compare Bempegaldesleukin with Nivolumab vs. Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
| Sponsor: | Bristol-Myers Squibb and Nektar Therapeutics |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAT1101 |
| U.S. Govt. ID: | NCT04410445 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of the study is to evaluate the effectiveness (how well the drug works) of the investigational drug called bempegaldesleukin when combined with drug nivolumab in comparison with nivolumab alone after complete resection (removal of all sites of known disease) of melanoma in participants at high risk of cancer returning after surgery (recurrence).
This study is closed
